NGS testing of the mutational BRCA1/2 status is recommended on both tumour DNA and germline DNA (peripheral blood cells), given that most of the BRCA1/2 mutations detected in tumours are germline (Gadducci et al., 2019; Personalised Medicine Commission, 2019b). The gene discussed is BRCA1; the disease is neoplasm.